• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Defiance ETFs Announces Closure of Select Funds

    1/16/26 4:40:23 PM ET
    $PLT
    $TRIL
    Telecommunications Equipment
    Public Utilities
    Major Pharmaceuticals
    Health Care
    Get the next $PLT alert in real time by email

    NEW YORK, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Tidal Financial Group and Defiance ETFs today announced their decision to close and liquidate eight exchange-traded funds listed on the Nasdaq:

    Defiance Leveraged Long + Income PLTR ETF (NASDAQ:PLT)

    Defiance Leveraged Long + Income SMCI ETF (NASDAQ:SMCC)

    Defiance Leveraged Long + Income HOOD ETF (NASDAQ:HOOI)

    Defiance Leveraged Long + Income Ethereum ETF (NASDAQ:ETHI)

    Defiance Leveraged Long + Income AMD ETF (NASDAQ:AMDU)

    Defiance Leveraged Long + Income HIMS ETF (NASDAQ:HIMY)

    Defiance Trillion Dollar Club Index ETF (NASDAQ:TRIL)

    Defiance Daily Target 2X Short LLY ETF (LLYZ)

    The Board of Trustees of Tidal Trust II approved this action as part of Defiance's ongoing review of its product lineup and its commitment to offering investors a focused suite of strategies aligned with evolving market conditions and investor demand.

    The final day of trading for the funds on the Nasdaq will be Monday, January 26, 2026. After the market close on this date, the funds will be delisted and will no longer accept creation orders. Shareholders who continue to hold shares as of each fund's liquidation date, Friday, January 30, 2026, will have their shares automatically redeemed for cash at the funds' net asset value (NAV) calculated on the liquidation date.

    Defiance encourages shareholders to consult their financial or tax advisors regarding the potential tax implications of the liquidation.

    About Tidal Financial Group

    Formed by ETF industry pioneers and thought leaders, Tidal Investments LLC is dedicated to revolutionizing ETF development, launch, marketing, and sales. With a focus on growing AUM, Tidal provides a comprehensive suite of services, proprietary tools, and methodologies designed to bring lasting investment ideas to market. Tidal is committed to ETF innovation, equipping issuers with the intelligence and tools needed to efficiently launch ETFs and optimize growth potential in a highly competitive space. For more information, visit www.tidalfinancialgroup.com.



    For further inquiries, please contact [email protected].

    Primary Logo

    Get the next $PLT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PLT
    $TRIL

    CompanyDatePrice TargetRatingAnalyst
    Trillium Therapeutics Inc.
    $TRIL
    11/17/2021Buy → Hold
    The Benchmark Company
    Trillium Therapeutics Inc.
    $TRIL
    11/17/2021Buy → Hold
    Benchmark
    Trillium Therapeutics Inc.
    $TRIL
    8/24/2021$21.00 → $18.50Buy → Hold
    Craig-Hallum
    Trillium Therapeutics Inc.
    $TRIL
    8/24/2021Market Outperform → Market Perform
    JMP Securities
    Trillium Therapeutics Inc.
    $TRIL
    8/23/2021$22.00 → $18.50Buy → Neutral
    HC Wainwright & Co.
    More analyst ratings

    $PLT
    $TRIL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Defiance ETFs Announces Closure of Select Funds

    NEW YORK, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Tidal Financial Group and Defiance ETFs today announced their decision to close and liquidate eight exchange-traded funds listed on the Nasdaq: Defiance Leveraged Long + Income PLTR ETF (NASDAQ:PLT)Defiance Leveraged Long + Income SMCI ETF (NASDAQ:SMCC)Defiance Leveraged Long + Income HOOD ETF (NASDAQ:HOOI)Defiance Leveraged Long + Income Ethereum ETF (NASDAQ:ETHI)Defiance Leveraged Long + Income AMD ETF (NASDAQ:AMDU)Defiance Leveraged Long + Income HIMS ETF (NASDAQ:HIMY)Defiance Trillion Dollar Club Index ETF (NASDAQ:TRIL)Defiance Daily Target 2X Short LLY ETF (LLYZ) The Board of Trustees of Tidal Trust II approved this action as part of Defia

    1/16/26 4:40:23 PM ET
    $PLT
    $TRIL
    Telecommunications Equipment
    Public Utilities
    Major Pharmaceuticals
    Health Care

    Defiance Launches $TRIL – The Trillion Dollar Club ETF: The New "Magnificent 7" of Global Markets

    NEW YORK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Defiance ETFs, a leader in innovative and first-mover exchange-traded funds, today announced the launch of the Defiance Trillion Dollar Club Index ETF (NASDAQ:TRIL), the first ETF designed to give investors exposure to the exclusive group of companies and crypto assets with market capitalizations above $1 trillion (the "Trillion Dollar Assets"). TRIL seeks to track the performance, before fees and expenses, of the BITA Trillion Dollar Club Index, which includes U.S. exchange-listed companies and U.S.-listed crypto ETFs tied to assets valued at $1 trillion or greater. As of September 15, 2025, the trillion-dollar club included Tesla, Alphabet,

    9/30/25 8:00:00 AM ET
    $TRIL
    Major Pharmaceuticals
    Health Care

    Defiance ETFs Launches Leveraged + Income ETFs for Palantir (PLT), Hims & Hers Health (HIMY), and Robinhood Markets (HOOI)

    MIAMI, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Defiance ETFs, a leading innovator in thematic and leveraged exchange-traded funds, today announced the launch of three new single-stock leveraged ETFs with income strategies: Defiance Leveraged Long + Income PLTR ETF (NASDAQ:PLT) – providing leveraged exposure to Palantir Technologies. Defiance Leveraged Long + Income HIMS ETF (NASDAQ:HIMY) – providing leveraged exposure to Hims & Hers Health. Defiance Leveraged Long + Income HOOD ETF (NASDAQ:HOOI) – providing leveraged exposure to Robinhood Markets. Each ETF combines approximately 150%–200% leveraged exposure to its underlying stock with an options-based credit call spread income strategy, des

    8/19/25 6:59:58 AM ET
    $PLT
    Telecommunications Equipment
    Public Utilities

    $PLT
    $TRIL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Walker Paul Edward returned 5,736,363 shares to the company

    4 - Trillium Therapeutics Inc. (0001616212) (Issuer)

    11/19/21 3:34:15 PM ET
    $TRIL
    Major Pharmaceuticals
    Health Care

    SEC Form 4 filed by Pucci Paolo

    4 - Trillium Therapeutics Inc. (0001616212) (Issuer)

    11/19/21 1:33:49 PM ET
    $TRIL
    Major Pharmaceuticals
    Health Care

    SEC Form 4 filed by Myers Scott Dunseth

    4 - Trillium Therapeutics Inc. (0001616212) (Issuer)

    11/19/21 1:33:02 PM ET
    $TRIL
    Major Pharmaceuticals
    Health Care

    $PLT
    $TRIL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Trillium Therapeutics downgraded by The Benchmark Company

    The Benchmark Company downgraded Trillium Therapeutics from Buy to Hold

    11/17/21 7:54:15 AM ET
    $TRIL
    Major Pharmaceuticals
    Health Care

    Trillium Therapeutics downgraded by Benchmark

    Benchmark downgraded Trillium Therapeutics from Buy to Hold

    11/17/21 6:38:15 AM ET
    $TRIL
    Major Pharmaceuticals
    Health Care

    Trillium Therapeutics downgraded by Craig-Hallum with a new price target

    Craig-Hallum downgraded Trillium Therapeutics from Buy to Hold and set a new price target of $18.50 from $21.00 previously

    8/24/21 8:29:10 AM ET
    $TRIL
    Major Pharmaceuticals
    Health Care

    $PLT
    $TRIL
    SEC Filings

    View All

    SEC Form 15-12B filed by Trillium Therapeutics Inc.

    15-12B - Trillium Therapeutics Inc. (0001616212) (Filer)

    11/29/21 6:31:18 AM ET
    $TRIL
    Major Pharmaceuticals
    Health Care

    SEC Form EFFECT filed by Trillium Therapeutics Inc.

    EFFECT - Trillium Therapeutics Inc. (0001616212) (Filer)

    11/22/21 12:15:09 AM ET
    $TRIL
    Major Pharmaceuticals
    Health Care

    SEC Form EFFECT filed by Trillium Therapeutics Inc.

    EFFECT - Trillium Therapeutics Inc. (0001616212) (Filer)

    11/22/21 12:15:09 AM ET
    $TRIL
    Major Pharmaceuticals
    Health Care

    $PLT
    $TRIL
    Leadership Updates

    Live Leadership Updates

    View All

    Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders and Appoints James T. Parsons to its Board of Directors

    Mr. Parsons served as the Chief Financial Officer of Trillium Therapeutics, which was recently acquired by Pfizer Inc. SAN DIEGO and CALGARY, AB, June 17, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), today announced the voting results from its Annual General Meeting (AGM) of Shareholders held on Thursday, June 16, 2022. A total of 40.43% of the issued and outstanding common shares of the Corporation were represented either in person or by proxy at the meeting. Additionally, James T. Parsons was elected to the Oncolytics Biotech Board of Directors. Leonard (Leon) Kruimer did not stand for re-election as a director at the AGM. Mr. Parsons commented, "Oncolytics' clini

    6/17/22 7:00:00 AM ET
    $DMAC
    $ONCY
    $TRIL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Major Pharmaceuticals

    Trillium Therapeutics Appoints Catherine Mackey, Ph.D., to Its Board of Directors

    CAMBRIDGE, Mass., June 30, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. ("Trillium" or the "Company") (TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the appointment of pharmaceutical industry leader Catherine Mackey, Ph.D., to its Board of Directors, effective immediately. "We are excited to welcome Dr. Mackey to our board of directors," said Paolo Pucci, Lead Director of Trillium.  "Her significant executive experience and expertise leading research and development organizations will be invaluable as Trillium advances its two lead product candidates into a Phase 1b/2 program." Dr. Mackey has more t

    6/30/21 7:00:00 AM ET
    $TRIL
    Major Pharmaceuticals
    Health Care

    Lifesize Appoints Former 8x8 (NASDAQ: EGHT) President, Cisco (NASDAQ: CSCO) and Polycom (NYSE: PLT) Senior Executive Kim Niederman as New CEO

    AUSTIN, Texas--(BUSINESS WIRE)--Lifesize, Inc., a leader and global provider of cloud contact center and video meeting solutions in over 100 countries with 1700 channel partners, today announced that its board of directors has appointed 30-year communications technology industry leader Kim Niederman as its new chief executive officer, effective immediately. Niederman will succeed Craig Malloy, one of the company’s original founders, who returned to the company as CEO in 2014. Today’s announcement is the next phase by the company to build an end-to-end enterprise communications offering, which started with the acquisition and merger of Lifesize with Serenova –– both Gartner-recogn

    2/24/21 1:00:00 PM ET
    $PLT
    $CSCO
    $EGHT
    Telecommunications Equipment
    Public Utilities
    Computer Communications Equipment
    Telecommunications

    $PLT
    $TRIL
    Financials

    Live finance-specific insights

    View All

    Pfizer to Acquire Trillium Therapeutics Inc.

    Proposed acquisition strengthens Pfizer's category leadership in Oncology with addition of next-generation, investigational immuno-therapeutics for hematological malignancies Expands innovative pipeline, potentially enhancing growth in 2026-2030 and beyond Pfizer to host analyst and investor call at 10:00 a.m. ET today with Pfizer Oncology executives Pfizer Inc. (NYSE:PFE) and Trillium Therapeutics Inc. (TSX:TRIL) today announced that the companies have entered into a definitive agreement under which Pfizer will acquire Trillium, a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. Under the terms of the agreement, Pfizer will acquire al

    8/23/21 6:45:00 AM ET
    $PFE
    $TRIL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Major Pharmaceuticals

    Poly Announces Fourth Quarter and Full-Year Fiscal 2021 Financial Results

    SANTA CRUZ, Calif., May 13, 2021 /PRNewswire/ -- Poly (NYSE:PLT), a global outfitter of professional-grade audio and video technology, today announced fourth quarter and full fiscal year results for the period ended April 3, 2021. Highlights for the fourth quarter include: Poly sales momentum continues with fiscal Q4 revenues growing 17% year over year, driven primarily by Video, which more than doubled to a record high, and Professional Headsets, which grew 20%, from the prior year quarter, reflecting the continued shift towards reliable, high-fidelity solutions for hybrid w

    5/13/21 4:05:00 PM ET
    $PLT
    Telecommunications Equipment
    Public Utilities

    Poly Announces Third Quarter Fiscal Year 2021 Financial Results

    SANTA CRUZ, Calif., Feb. 4, 2021 /PRNewswire/ -- Poly (NYSE: PLT), a global outfitter of professional-grade audio and video technology, today announced third quarter results for the period ended December 26, 2020. Highlights for the third quarter include: Poly posted record Professional Headset and Video revenues, with unit shipments more than doubling in each category year over year, reflecting the massive shift in the way work is done, where work is done, and the importance of reliable, high-fidelity connectivity. The Company announced the Poly Studio P Series, a new family of sophisticated prosumer video solutions, addressing the growing need for tools that allow professionals to w

    2/4/21 4:05:00 PM ET
    $PLT
    Telecommunications Equipment
    Public Utilities

    $PLT
    $TRIL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Trillium Therapeutics Inc. (Amendment)

    SC 13D/A - Trillium Therapeutics Inc. (0001616212) (Subject)

    11/19/21 6:44:02 AM ET
    $TRIL
    Major Pharmaceuticals
    Health Care

    SEC Form SC 13G/A filed by Trillium Therapeutics Inc. (Amendment)

    SC 13G/A - Trillium Therapeutics Inc. (0001616212) (Subject)

    4/7/21 4:32:50 PM ET
    $TRIL
    Major Pharmaceuticals
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - Trillium Therapeutics Inc. (0001616212) (Subject)

    2/16/21 5:17:54 PM ET
    $TRIL
    Major Pharmaceuticals
    Health Care